Atrium Therapeutics Receives FDA Clearance for ATR 1072 IND
Atrium Therapeutics obtained FDA clearance to launch the Phase 1/2 Corventis trial for the precision cardiology candidate ATR 1072. This regulatory milestone validates the company's approach to treating rare genetic cardiomyopathies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day